



# Abbott Laboratories (Pakistan) Limited

City Office: 11th & 12th Floors  
Ocean Tower, G-3, Block 9  
Main Clifton Road, Karachi 75600.  
P.O. Box 13841  
Tel: +92-21-111-Abbott (111-222-688)

# Abbott Laboratories (Pakistan) Limited

Registered Office:  
Opp, Radio Pakistan Transmission Centre,  
Hyderabad Road, Landhi Karachi 75120  
P.O. Box 7229 Karachi 74400  
Tel: +92-21-111-Abbott (111-222-688)

October 29th, 2025

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi

## Sub: Financial Results for the Nine months and Quarter ended September 30th, 2025

Dear Sir,

We have to inform you that the Board of Directors' of our company in their meeting held on Wednesday, October 29th, 2025 at 12:00 p.m. at Abbott Laboratories (Pakistan) Limited, 11th Floor, Ocean Tower, G-3, Block-9, Main Clifton Road, Karachi, considered and approved the financial results of the Company as follows:

	<u>Nine Months Ended</u>		<u>Three Months Ended</u>	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
	----- (Rupees in ' 000) -----			
<b>SALES- NET</b>				
Local	53,909,372	47,273,134	18,995,527	16,784,001
Export	2,317,551	2,290,945	823,607	580,545
	<u>56,226,923</u>	<u>49,564,079</u>	<u>19,819,134</u>	<u>17,364,546</u>
Cost of sales	(36,886,086)	(35,493,642)	(13,093,197)	(11,634,162)
<b>GROSS PROFIT</b>	<u>19,340,837</u>	<u>14,070,437</u>	<u>6,725,937</u>	<u>5,730,384</u>
Selling and distribution expenses	(8,501,410)	(7,120,361)	(2,974,143)	(2,404,851)
Administrative expenses	(972,482)	(857,385)	(334,287)	(300,482)
Other charges	(1,256,699)	(578,954)	(430,365)	(250,259)
Other income	603,335	541,111	186,590	83,003
	<u>(10,127,256)</u>	<u>(8,015,589)</u>	<u>(3,552,205)</u>	<u>(2,872,589)</u>
	9,213,581	6,054,848	3,173,732	2,857,795
Finance costs	(55,363)	(18,587)	(17,659)	(5,988)
<b>PROFIT BEFORE TAXATION</b>	<u>9,158,218</u>	<u>6,036,261</u>	<u>3,156,073</u>	<u>2,851,807</u>
Minimum tax differential	(146,989)	(87,306)	(146,989)	79,576
	<u>9,011,229</u>	<u>5,948,955</u>	<u>3,009,084</u>	<u>2,931,383</u>
<b>INCOME TAX</b>				
Current -For the year	(3,828,736)	(1,913,620)	(1,181,163)	(1,182,528)
-Prior year	-	32,253	-	32,253
Deferred	183,225	(118,305)	(5,375)	28,035
	<u>(3,645,511)</u>	<u>(1,999,672)</u>	<u>(1,186,538)</u>	<u>(1,122,240)</u>
<b>NET PROFIT FOR THE PERIOD</b>	<u>5,365,718</u>	<u>3,949,283</u>	<u>1,822,546</u>	<u>1,809,143</u>
<b>BASIC AND DILUTED EARNINGS PER SHARE (Rs. per share)</b>	<u>54.81</u>	<u>40.34</u>	<u>18.62</u>	<u>18.48</u>

N



The Quarterly Report of the Company for the period ended September 30, 2025 will be transmitted through PUCARS separately, within the specified time.


Yours faithfully,  
ABBOTT LABORATORIES (PAKISTAN) LIMITED

  
SYED ANIS AHMED  
CHIEF EXECUTIVE &  
MANAGING DIRECTOR

**ABBOTT LABORATORIES (PAKISTAN) LIMITED**  
**CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION**  
**AS AT SEPTEMBER 30, 2025**

		September 30, 2025	December 31, 2024
	Note	----- Rupees in '000 ----- (Un-audited)	(Audited)
<b><u>ASSETS</u></b>			
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	6	14,702,339	14,252,797
Intangible assets		884	1,250
Long-term loans and advances		129,237	114,226
Long-term deposits		32,713	7,513
Long-term prepayments		10,078	13,710
		<u>14,875,251</u>	<u>14,389,496</u>
<b>CURRENT ASSETS</b>			
Stores and spares		570,438	529,619
Stock-in-trade	7	13,517,073	10,694,515
Trade debts		3,390,553	2,982,679
Loans and advances	8	1,047,173	938,021
Trade deposits and short-term prepayments	9	555,581	283,813
Other receivables	10	1,330,418	1,182,530
Taxation - net		240,470	468,136
Cash and cash equivalents	11	9,009,546	6,182,349
		<u>29,661,252</u>	<u>23,261,662</u>
<b>TOTAL ASSETS</b>		<u><b>44,536,503</b></u>	<u><b>37,651,158</b></u>
<b><u>EQUITY AND LIABILITIES</u></b>			
<b>SHARE CAPITAL AND RESERVES</b>			
<b>Authorised capital</b>			
200,000,000 ordinary shares of Rs.10 each		<u>2,000,000</u>	<u>2,000,000</u>
<b>Issued, subscribed and paid-up capital</b>	12	979,003	979,003
<b>Reserves</b>			
- Capital		1,993,957	1,750,481
- Revenue		25,381,867	20,995,152
		<u>27,375,824</u>	<u>22,745,633</u>
		<u>28,354,827</u>	<u>23,724,636</u>
<b>NON-CURRENT LIABILITIES</b>			
Deferred taxation - net		869,361	1,052,587
Staff retirement benefits		1,230,791	1,184,179
Lease liabilities		349,206	29,545
		<u>2,449,358</u>	<u>2,266,311</u>
<b>CURRENT LIABILITIES</b>			
Trade and other payables	13	12,681,033	10,951,662
Unclaimed dividends		71,605	63,715
Unpaid dividends		209,714	-
Current maturity of lease liabilities		85,873	22,683
Provisions		684,093	622,151
		<u>13,732,318</u>	<u>11,660,211</u>
<b>CONTINGENCIES AND COMMITMENTS</b>	14		
<b>TOTAL EQUITY AND LIABILITIES</b>		<u><b>44,536,503</b></u>	<u><b>37,651,158</b></u>


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



CHIEF EXECUTIVE OFFICER



DIRECTOR



CHIEF FINANCIAL OFFICER

**ABBOTT LABORATORIES (PAKISTAN) LIMITED**  
**CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS**  
**FOR THE NINE MONTHS AND THREE MONTHS ENDED SEPTEMBER 30, 2025**  
**(UN-AUDITED)**

		Nine Months Ended		Three Months Ended	
		September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
Note		----- Rupees in '000 -----			
<b>SALES - NET</b>					
Local		53,909,372	47,273,134	18,995,527	16,784,001
Export		2,317,551	2,290,945	823,607	580,545
		56,226,923	49,564,079	19,819,134	17,364,546
Cost of sales		(36,886,086)	(35,493,642)	(13,093,197)	(11,634,162)
<b>GROSS PROFIT</b>		19,340,837	14,070,437	6,725,937	5,730,384
Selling and distribution expenses		(8,501,410)	(7,120,361)	(2,974,143)	(2,404,851)
Administrative expenses		(972,482)	(857,385)	(334,287)	(300,482)
Other charges	15	(1,256,699)	(578,954)	(430,365)	(250,259)
Other income	16	603,335	541,111	186,590	83,003
		(10,127,256)	(8,015,589)	(3,552,205)	(2,872,589)
		9,213,581	6,054,848	3,173,732	2,857,795
Finance costs		(55,363)	(18,587)	(17,659)	(5,988)
<b>PROFIT BEFORE TAXATION</b>		9,158,218	6,036,261	3,156,073	2,851,807
Minimum tax differential		(146,989)	(87,306)	(146,989)	79,576
		9,011,229	5,948,955	3,009,084	2,931,383
<b>INCOME TAX</b>					
Current	- For the year	(3,828,736)	(1,913,620)	(1,181,163)	(1,182,528)
	- Prior year	-	32,253	-	32,253
Deferred		183,225	(118,305)	(5,375)	28,035
		(3,645,511)	(1,999,672)	(1,186,538)	(1,122,240)
<b>NET PROFIT FOR THE PERIOD</b>		5,365,718	3,949,283	1,822,546	1,809,143
<b>BASIC AND DILUTED EARNINGS PER SHARE</b>					
<b>(Rs. per share)</b>		54.81	40.34	18.62	18.48


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



**CHIEF EXECUTIVE OFFICER**



**DIRECTOR**



**CHIEF FINANCIAL OFFICER**

**ABBOTT LABORATORIES (PAKISTAN) LIMITED**  
**CONDENSED INTERIM STATEMENT OF CASH FLOWS**  
**FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025**  
**(UN-AUDITED)**

		September 30, 2025 (Un-audited) ---- Rupees in '000 ----	September 30, 2024 (Un-audited) ---- Rupees in '000 ----
	Note		
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Cash generated from operations	17	9,020,548	4,136,473
Income taxes paid		(3,748,060)	(2,411,024)
Long-term loans and advances - net		(15,011)	(12,953)
Long-term deposits - net		(25,200)	-
Long-term prepayments - net		3,632	(10,416)
Contributions to staff retirement benefit funds		(253,147)	(218,923)
Net movement in provisions		61,942	-
<b>Net cash inflow from operating activities</b>		<b>5,044,704</b>	<b>1,483,157</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Additions to operating fixed assets and CWIP	6.1	(1,893,111)	(1,925,266)
Sale proceeds from disposal of property, plant and equipment		177,968	85,500
Interest income		345,737	329,970
<b>Net cash outflow from investing activities</b>		<b>(1,369,406)</b>	<b>(1,509,796)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Finance costs paid		(7,571)	(8,811)
Lease rentals paid		(79,131)	(117,729)
Dividends paid		(761,399)	(1,030,325)
<b>Net cash outflow from financing activities</b>		<b>(848,101)</b>	<b>(1,156,865)</b>
<b>NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS</b>		<b>2,827,197</b>	<b>(1,183,504)</b>
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</b>		<b>6,182,349</b>	<b>5,036,712</b>
<b>CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</b>	17.2	<b>9,009,546</b>	<b>3,853,208</b>


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



**CHIEF EXECUTIVE OFFICER**



**DIRECTOR**



**CHIEF FINANCIAL OFFICER**

**ABBOTT LABORATORIES (PAKISTAN) LIMITED**  
**CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY**  
**FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025**

Share Capital	Reserves					Total Equity
	Capital Reserves		Revenue Reserves		Total	
	Reserve Arising on Merger	Other	General Reserve	Un-appropriated Profit		

----- Rupees in '000 -----

**Balance as at January 1, 2024 (Audited)**                      979,003              46,097              1,391,065              5,338,422              10,482,759              17,258,343              18,237,346

**Transactions with owners, recorded directly in equity**

Employee benefit cost under IFRS 2- 'Share based payments'              -              -              244,953              -              -              244,953              244,953

**Total comprehensive income for the period ended September 30, 2024**

Net profit for the period	-	-	-	-	3,949,283	3,949,283	3,949,283
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	3,949,283	3,949,283	3,949,283

**Balance as at September 30, 2024 (Un-audited)**                      979,003              46,097              1,636,018              5,338,422              14,432,042              21,452,579              22,431,582

**Balance as at January 01, 2025 (Audited)**                      979,003              46,097              1,704,384              5,338,422              15,656,730              22,745,633              23,724,636

Final dividend for the year ended December 31, 2024  
@ Rs. 10/- per share                      -              -              -              -              (979,003)              (979,003)              (979,003)

Employee benefit cost under IFRS 2- 'Share based payments'              -              -              243,476              -              -              243,476              243,476

**Total comprehensive income for the period ended September 30, 2025**

Net profit for the period	-	-	-	-	5,365,718	5,365,718	5,365,718
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	5,365,718	5,365,718	5,365,718

**Balance as at Septmeber 30, 2025 (Un-audited)**                      979,003              46,097              1,947,860              5,338,422              20,043,445              27,375,824              28,354,827


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



**CHIEF EXECUTIVE OFFICER**



**DIRECTOR**



**CHIEF FINANCIAL OFFICER**